Targeting T Cell Checkpoints 41BB and LAG3 and Myeloid Cell CXCR1/CXCR2 Results in Antitumor Immunity and Durable Response in Pancreatic Cancer

Researchers systematically characterized the mechanisms underlying de novo immune checkpoint therapy resistance and identified effective therapeutic options for PDAC.